Global Pharmaceutical Company Licenses Ajinomoto’s Corynex™ Recombinant
Protein Expression System Following Successful Proof-of-Concept
Ajinomoto Enables Pharma to Research and Develop Difficult to Express Proteins
RALEIGH, N.C. -- March 5, 2013
Ajinomoto North America, Inc. today announced a top-tier, global
pharmaceutical company has licensed its Corynex^TM Recombinant Protein
Expression System. The pharma assessed the Technology with a number of
recombinant proteins. Based upon a successful proof-of-concept, the company
has entered a full licensing agreement that allows for the in-house use of
Ajinomoto’s proprietary Corynex^TM Expression.
Corynex^TM uses the gram-positive Corynebacterium glutamicum to reduce
purification steps, lower costs, and increase yield. Corynex^TM does not
require cell lysis or protein refolding, eliminating the need for endotoxin
removal steps. The system also speeds production through a fast-growing
bacterial model, shorter fermentation run to produce proteins and cheaper
bacterium medium cost.
Ajinomoto was initially tasked with expressing a viable level of a series of
proteins for the global pharma, several of which had prior low levels of
expression when using traditional microbial expression platforms. Preliminary
results showed that with the development of protease deficient strains,
Ajinomoto successfully expressed over 50% of the proteins within the study.
This high success rate showcased the market potential for the Corynebacterium
glutamicum expression method – especially with proteins that traditional
expression systems had struggled to express. “We are pleased to extend a
licensing agreement with a top-tier pharmaceutical company to build upon our
initial successful proof-of-concept efforts,” Joel White, business manager of
To read more about Ajinomoto’s successes and lessons learned using its
Corynex^TM Recombinant Protein Expression System, please visit
www.corynex.com. In addition to two case studies, you can download a related
whitepaper, “Speeding and Simplifying Recombinant Protein Production ” and
view video animation of the expression and export of recombinant proteins from
Companies looking to bring this proven expression system in-house for the
development of their own proprietary proteins should contact Joel White
directly at email@example.com or 919.723.2116.
About Ajinomoto North America, Inc.
Ajinomoto is the leading global supplier of pharmaceutical and research-grade
amino acids. Leveraging its unrivaled foundation of more than 50 years
experience identifying, refining, and marketing amino acids, Ajinomoto North
America, Inc. continues to innovate and set new industry standards for
manufacturing and related services within the fermentation and expression
fields. Building on its legacy, Amino Acid Technologies has transitioned the
same level of quality and performance into new core competencies in the areas
of recombinant protein expression and peptide synthesis. These new processes
enable pharmaceutical and biotech companies to develop high-quality products
that were previously thought to be too complicated or expensive to produce.
Ajinomoto North America, Inc. is a wholly-owned subsidiary of Ajinomoto Co.,
Inc. For more information, please refer to
Crossroads Public Relations for Ajinomoto North America, Inc.
Molly Thompson, 919-821-2822
Press spacebar to pause and continue. Press esc to stop.